The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Cited by
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Self-citationOstrom, Q. T., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab200 · Cited by 2,529
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Ostrom, Q. T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., & Barnholtz-Sloan, J. S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy131 · Cited by 2,138
Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa200 · Cited by 1,789
Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac202 · Cited by 1,565
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
“Cancer type-specific events that occurred together with high expression (data derived from Northcott et al. 44 ) included alterations of RIMS2 45 .”
Self-citationThe chromatin accessibility landscape of primary human cancers
Corces, M. R., Granja, J. M., Shams, S., Louie, B. H., Seoane, J. A., Zhou, W., Silva, T. C., Groeneveld, C., Wong, C. K., Cho, S. W., et al. (2018) · Science · doi:10.1126/science.aav1898 · Cited by 1,230
“Consistent with published reports (12, 18, 29, 30), the degree of DNA methylation was anticorrelated with chromatin accessibility at regulatory elements, and regions lacking chromatin accessibilityweremore frequentlymethylated (fig.”
ResultSelf-citationNavigating the DNA methylation landscape of cancer
Nishiyama, A., & Nakanishi, M. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.05.002 · Cited by 972
Structural variation in the 3D genome
Spielmann, M., Lupiáñez, D. G., & Mundlos, S. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0007-0 · Cited by 726
Northcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0063-6 · Cited by 649
Self-citationCancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Childhood cerebellar tumours mirror conserved fetal transcriptional programs
Vladoiu, M. C., El-Hamamy, I., Donovan, L. K., Farooq, H., Holgado, B. L., Sundaravadanam, Y., Ramaswamy, V., Hendrikse, L. D., Kumar, S., Mack, S. C., et al. (2019) · Nature · doi:10.1038/s41586-019-1158-7 · Cited by 426
Self-citationResolving medulloblastoma cellular architecture by single-cell genomics
Hovestadt, V., Smith, K. S., Bihannic, L., Filbin, M. G., Shaw, M. L., Baumgartner, A., DeWitt, J. C., Groves, A., Mayr, L., Weisman, H. R., et al. (2019) · Nature · doi:10.1038/s41586-019-1434-6 · Cited by 402
Self-citationWaszak, S. M., Northcott, P. A., Buchhalter, I., Robinson, G. W., Sutter, C., Groebner, S., Grund, K. B., Brugières, L., Jones, D. T. W., Pajtler, K. W., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30242-0 · Cited by 395
Self-citationWong, M., Mayoh, C., Lau, L. M. S., Khuong-Quang, D.-A., Pinese, M., Kumar, A., Barahona, P., Wilkie, E. E., Sullivan, P., Bowen-James, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1072-4 · Cited by 393
Highly rearranged chromosomes reveal uncoupling between genome topology and gene expression
Ghavi-Helm, Y., Jankowski, A., Meiers, S., Viales, R. R., Korbel, J. O., & Furlong, E. E. M. (2019) · Nature Genetics · doi:10.1038/s41588-019-0462-3 · Cited by 354
Self-citationIntegrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer
Petralia, F., Tignor, N., Reva, B., Koptyra, M., Chowdhury, S., Rykunov, D., Krek, A., Ma, W., Zhu, Y., Ji, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.044 · Cited by 317
“Because pediatric brain tumors have a relatively low mutational burden (Chalmers et al., 2017; Gröbner et al., 2018; Northcott et al., 2017; Parsons et al., 2011; Pugh et al., 2012; Robinson et al., creativecommons.org/licenses/by-nc-nd/4.0/).”
BackgroundInfluentialSelf-citationDetecting the mutational signature of homologous recombination deficiency in clinical samples
Gulhan, D. C., Lee, J. J.-K., Melloni, G. E. M., Cortés-Ciriano, I., & Park, P. J. (2019) · Nature Genetics · doi:10.1038/s41588-019-0390-2 · Cited by 314
Risk factors for childhood and adult primary brain tumors
Ostrom, Q. T., Fahmideh, M. A., Cote, D. J., Muskens, I. S., Schraw, J. M., Scheurer, M. E., & Bondy, M. L. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz123 · Cited by 314
Sharma, T., Schwalbe, E. C., Williamson, D., Sill, M., Hovestadt, V., Mynarek, M., Rutkowski, S., Robinson, G. W., Gajjar, A., Cavalli, F., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02020-0 · Cited by 310
Self-citationUdaka, Y. T., & Packer, R. J. (2018) · Neurologic Clinics · doi:10.1016/j.ncl.2018.04.009 · Cited by 280
Stalled developmental programs at the root of pediatric brain tumors
Jessa, S., Blanchet-Cohen, A., Krug, B., Vladoiu, M., Coutelier, M., Faury, D., Poreau, B., De Jay, N., Hébert, S., Monlong, J., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0531-7 · Cited by 285
Self-citationJuraschka, K., & Taylor, M. D. (2019) · Journal of Neurosurgery: Pediatrics · doi:10.3171/2019.5.peds18381 · Cited by 275
Self-citationMedulloblastomics revisited: biological and clinical insights from thousands of patients
Hovestadt, V., Ayrault, O., Swartling, F. J., Robinson, G. W., Pfister, S. M., & Northcott, P. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0223-8 · Cited by 271
Self-citationSt. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem
McLeod, C., Gout, A. M., Zhou, X., Thrasher, A., Rahbarinia, D., Brady, S. W., Macias, M., Birch, K., Finkelstein, D., Sunny, J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1230 · Cited by 259
Self-citationDonovan, L. K., Delaidelli, A., Joseph, S. K., Bielamowicz, K., Fousek, K., Holgado, B. L., Manno, A., Srikanthan, D., Gad, A. Z., Van Ommeren, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0827-2 · Cited by 246
Self-citationGajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., Mahajan, A., Su, J., Bouffet, E., Bartels, U., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01372 · Cited by 241
Self-citationRobinson, G. W., Rudneva, V. A., Buchhalter, I., Billups, C. A., Waszak, S. M., Smith, K. S., Bowers, D. C., Bendel, A., Fisher, P. G., Partap, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30204-3 · Cited by 234
Self-citationthe Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Frankell, A. M., Jammula, S., Li, X., Contino, G., Killcoyne, S., Abbas, S., Perner, J., Bower, L., Devonshire, G., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0331-5 · Cited by 231
Weller, R. O., Sharp, M. M., Christodoulides, M., Carare, R. O., & Møllgård, K. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1809-z · Cited by 222
“Four major molecular subgroups of medulloblastoma have been recognised: wingless (WNT), sonic hedgehog (SHH), group 3 and group 4 [77] but whole genome landscapes have revealed additional new molecular subtypes [69].”
BackgroundCancer proteogenomics: current impact and future prospects
Mani, D. R., Krug, K., Zhang, B., Satpathy, S., Clauser, K. R., Ding, L., Ellis, M., Gillette, M. A., & Carr, S. A. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00446-5 · Cited by 229
A pan-cancer analysis of synonymous mutations
Sharma, Y., Miladi, M., Dukare, S., Boulay, K., Caudron-Herger, M., Groß, M., Backofen, R., & Diederichs, S. (2019) · Nature Communications · doi:10.1038/s41467-019-10489-2 · Cited by 225
The genomic landscape of pediatric cancers: Implications for diagnosis and treatment
Sweet-Cordero, E. A., & Biegel, J. A. (2019) · Science · doi:10.1126/science.aaw3535 · Cited by 225
Michalski, J. M., Janss, A. J., Vezina, L. G., Smith, K. S., Billups, C. A., Burger, P. C., Embry, L. M., Cullen, P. L., Hardy, K. K., Pomeroy, S. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02730 · Cited by 215
“The resulting group 3 and group 4 subgroup assignments were further evaluated by implementing another ExtraTrees classifier trained on a reference data set of 740 previously classified group 3 and group 4 tumors.(22) Copy number variation analysis frommethylation array data was performed using the Conumee Bioconductor…”
MethodSelf-citationPfister, S. M., Reyes-Múgica, M., Chan, J. K. C., Hasle, H., Lazar, A. J., Rossi, S., Ferrari, A., Jarzembowski, J. A., Pritchard-Jones, K., Hill, D. A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1094 · Cited by 212
Self-citationMolecular pathology of tumors of the central nervous system
Kristensen, B. W., Priesterbach-Ackley, L. P., Petersen, J. K., & Wesseling, P. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz164 · Cited by 213
Grabovska, Y., Mackay, A., O’Hare, P., Crosier, S., Finetti, M., Schwalbe, E. C., Pickles, J. C., Fairchild, A. R., Avery, A., Cockle, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18070-y · Cited by 213
Archer, T. C., Ehrenberger, T., Mundt, F., Gold, M. P., Krug, K., Mah, C. K., Mahoney, E. L., Daniel, C. J., LeNail, A., Ramamoorthy, D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.004 · Cited by 202
“While MYC amplification is a ‘‘hallmark’’ of MYC-activated medulloblastoma, it does not occur in every tumor of this type (Cho et al., 2011; Northcott et al., 2017).”
Self-citationPeneder, P., Stütz, A. M., Surdez, D., Krumbholz, M., Semper, S., Chicard, M., Sheffield, N. C., Pierron, G., Lapouble, E., Tötzl, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23445-w · Cited by 200
A biobank of patient-derived pediatric brain tumor models
Brabetz, S., Leary, S. E. S., Gröbner, S. N., Nakamoto, M. W., Şeker-Cin, H., Girard, E. J., Cole, B., Strand, A. D., Bloom, K. L., Hovestadt, V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0207-3 · Cited by 176
Self-citationSerial assessment of measurable residual disease in medulloblastoma liquid biopsies
Liu, A. P. Y., Smith, K. S., Kumar, R., Paul, L., Bihannic, L., Lin, T., Maass, K. K., Pajtler, K. W., Chintagumpala, M., Su, J. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.012 · Cited by 177
Self-citationModeling medulloblastoma in vivo and with human cerebellar organoids
Ballabio, C., Anderle, M., Gianesello, M., Lago, C., Miele, E., Cardano, M., Aiello, G., Piazza, S., Caron, D., Gianno, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13989-3 · Cited by 175
“We decided to focus on all the genetic alterations present in Group 3 MB patients with a frequency higher than 2% or genes that show differential expression (higher than 16-folds) compared with normal cerebellum 23 (see the Methods section).”
Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma
Suzuki, H., Kumar, S. A., Shuai, S., Diaz-Navarro, A., Gutierrez-Fernandez, A., De Antonellis, P., Cavalli, F. M. G., Juraschka, K., Farooq, H., Shibahara, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1650-0 · Cited by 172
Self-citationLeary, S. E. S., Packer, R. J., Li, Y., Billups, C. A., Smith, K. S., Jaju, A., Heier, L., Burger, P., Walsh, K., Han, Y., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2224 · Cited by 164
Self-citationThandapani, P. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.014 · Cited by 163
Germline Elongator mutations in Sonic Hedgehog medulloblastoma
Waszak, S. M., Robinson, G. W., Gudenas, B. L., Smith, K. S., Forget, A., Kojic, M., Garcia-Lopez, J., Hadley, J., Hamilton, K. V., Indersie, E., et al. (2020) · Nature · doi:10.1038/s41586-020-2164-5 · Cited by 162
Self-citationMolecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
Jones, D. T. W., Banito, A., Grünewald, T. G. P., Haber, M., Jäger, N., Kool, M., Milde, T., Molenaar, J. J., Nabbi, A., Pugh, T. J., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0169-x · Cited by 161
Self-citationUnified rhombic lip origins of group 3 and group 4 medulloblastoma
Smith, K. S., Bihannic, L., Gudenas, B. L., Haldipur, P., Tao, R., Gao, Q., Li, Y., Aldinger, K. A., Iskusnykh, I. Y., Chizhikov, V. V., et al. (2022) · Nature · doi:10.1038/s41586-022-05208-9 · Cited by 187
Self-citationWang, X., Xu, J., Zhang, B., Hou, Y., Song, F., Lyu, H., & Yue, F. (2021) · Nature Methods · doi:10.1038/s41592-021-01164-w · Cited by 164
Failure of human rhombic lip differentiation underlies medulloblastoma formation
Hendrikse, L. D., Haldipur, P., Saulnier, O., Millman, J., Sjoboen, A. H., Erickson, A. W., Ong, W., Gordon, V. D., Coudière-Morrison, L., Mercier, A. L., et al. (2022) · Nature · doi:10.1038/s41586-022-05215-w · Cited by 181
Self-citationA first-generation pediatric cancer dependency map
Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhayay, P., Wechsler, C. S., Fung, I., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00819-w · Cited by 153
Pathology, diagnostics, and classification of medulloblastoma
Orr, B. A. (2020) · Brain Pathology · doi:10.1111/bpa.12837 · Cited by 201
“Other genes commonly mutated in WNT MB include TP53 , SMARCA4 , KMT2D and DDX3X (34,51,68).”
InfluentialPrecision medicine in pediatric oncology
Forrest, S. J., Geoerger, B., & Janeway, K. A. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000570 · Cited by 179
Jiang, Y., Wang, J., Sun, M., Zuo, D., Wang, H., Shen, J., Jiang, W., Mu, H., Ma, X., Yin, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34689-5 · Cited by 172
Self-citationForget, A., Martignetti, L., Puget, S., Calzone, L., Brabetz, S., Picard, D. J., Montagud, A., Liva, S., Sta, A., Dingli, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.002 · Cited by 167
“…profiling were successfully implemented to identify these two subgroups and distinguish them from group 3 (G3) and group 4 (G4) MBs (Cavalli et al., 2017; Gottardo et al., 2014; Hovestadt et al., 2013; Northcott et al., 2011, 2017; Remke et al., 2011b; Schwalbe et al., 2017; Shih et al., 2014).”
BackgroundMethodSelf-citationRiemondy, K. A., Venkataraman, S., Willard, N., Nellan, A., Sanford, B. L., Griesinger, A. M., Amani, V. M., Mitra, S. S., Hankinson, T. C., Handler, M. H., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noab135 · Cited by 171
The developmental origin of brain tumours: a cellular and molecular framework
Azzarelli, R., Simons, B. D., & Philpott, A. (2018) · Development · doi:10.1242/dev.162693 · Cited by 156
“Importantly, certain types of chromatinmodifying alterations are restricted to specific subgroups of tumours, as has been shown in medulloblastoma (Northcott et al., 2017; Robinson et al., 2012), and might thus impart lineage-specific vulnerabilities to distinct types of tumour cells.”
BackgroundBrain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity
Gimple, R. C., Yang, K., Halbert, M. E., Agnihotri, S., & Rich, J. N. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00486-x · Cited by 154
MR Imaging–Based Radiomic Signatures of Distinct Molecular Subgroups of Medulloblastoma
Iv, M., Zhou, M., Shpanskaya, K. S., Perreault, S., Wang, Z., Tranvinh, E., Lanzman, B., Vajapeyam, S., Vitanza, N. A., Fisher, P. G., et al. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5899 · Cited by 132
“Several brain tumors are known to have spatial molecular 1,9,30,31 and imaging 13,22,23,25,26 heterogeneity.”
Self-citationSubgroup-specific immune and stromal microenvironment in medulloblastoma
Bockmayr, M., Mohme, M., Klauschen, F., Winkler, B., Budczies, J., Rutkowski, S., & Schüller, U. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1462430 · Cited by 121
“Recently, large gene expression datasets of medulloblastoma have been released, including one dataset of 763 tumors.(4,5)”
BackgroundCancer cell heterogeneity & plasticity in glioblastoma and brain tumors
Lauko, A. J., Lo, A., Ahluwalia, M. S., & Lathia, J. D. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.014 · Cited by 152
Escudero, L., Llort, A., Arias, A., Díaz‐Navarro, A., Ricarte, F. M., Rubio-Pérez, C., Mayor, R., Caratù, G., Martínez-Sáez, E. A., Méndez, E. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19175-0 · Cited by 140
Conumee 2.0: enhanced copy-number variation analysis from DNA methylation arrays for humans and mice
Daenekas, B., Pérez, E., Boniolo, F., Ştefan, S., Benfatto, S., Sill, M., Sturm, D., Jones, D., Capper, D., Zapatka, M., et al. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae029 · Cited by 161
“With nearly 20 000 down-loads, conumee is one of the most widely used tools for inferring CNVs from DNA methylation arrays and has been applied in numerous large-scale cancer research projects (Sturm et al. 2016, Northcott et al. 2017).”
MethodSelf-citationLeveraging base-pair mammalian constraint to understand genetic variation and human disease
Sullivan, P. F., Meadows, J. R. S., Gazal, S., Phan, B. N., Li, X., Genereux, D. P., Dong, M. X., Bianchi, M., Andrews, G., Sakthikumar, S., et al. (2023) · Science · doi:10.1126/science.abn2937 · Cited by 143
“, wingless/ integrated (WNT), sonic hedgehog signaling (SHH), group 3 and group 4) (62).”
An update on the central nervous system manifestations of DICER1 syndrome
de Kock, L., Priest, J. R., Foulkes, W. D., & Alexandrescu, S. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01997-y · Cited by 118
“However, as discussed above, profiling of the genomic landscapes of medulloblastoma strongly suggests medulloblastoma is not a DICER1 syndrome tumor [43].”
BackgroundFerris, S. P., Vega, J. E. V., Aboian, M., Lee, J. C., Ziffle, J. V., Onodera, C. S., Grenert, J. P., Saunders, T., Chen, Y.-Y., Banerjee, A., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12747 · Cited by 119
“None of the cases contained MYC or MYCN amplification that are common in Groups 3 and 4 medulloblastomas, as well as a subset of pediatric glioblastomas (14, 16).”
BackgroundRecent progress in the treatment of cancer in children
Butler, E. B., Ludwig, K. F., Pacenta, H. L., Klesse, L. J., Watt, T. C., & Laetsch, T. W. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21665 · Cited by 154
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome
Hartlieb, S., Sieverling, L., Nadler-Holly, M., Ziehm, M., Toprak, U. H., Herrmann, C., Ishaque, N., Okonechnikov, K., Gartlgruber, M., Park, Y.-G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21247-8 · Cited by 121
Self-citationMedulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies
Wang, J., Garancher, A., Ramaswamy, V., & Wechsler-Reya, R. J. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-013838 · Cited by 113
Self-citationDomenico, A. D., Pipinikas, C., Maire, R., Bräutigam, K., Simillion, C., Dettmer, M. S., Vassella, E., Thirlwell, C., Perren, A. A., & Marinoni, I. (2020) · Communications Biology · doi:10.1038/s42003-020-01479-y · Cited by 115
Goschzik, T., Schwalbe, E. C., Hicks, D., Smith, A. J., Muehlen, A. Z., Figarella‐Branger, D., Doz, F., Rutkowski, S., Lannering, B., Pietsch, T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30532-1 · Cited by 114
Li, B. K., Vasiljevic, A., Dufour, C., Yao, F., Ho, B., Lu, M., Hwang, E. I., Gururangan, S., Hansford, J. R., Fouladi, M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02111-y · Cited by 118
Self-citationA unified haplotype-based method for accurate and comprehensive variant calling
Cooke, D. P., Wedge, D. C., & Lunter, G. A. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00861-3 · Cited by 117
Cohen, A. R. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2116344 · Cited by 130
Structural variations in cancer and the 3D genome
Dubois, F. P. B., Sidiropoulos, N., Weischenfeldt, J., & Beroukhim, R. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00488-9 · Cited by 127
“Since then, similar examples of enhancer hijacking have been observed across multiple SVs and cancer types 7,124–126 .”
BackgroundSelf-citationTumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma
Maximov, V. D., Chen, Z., Wei, Y., Robinson, M. H., Herting, C. J., Shanmugam, N., Rudneva, V. A., Goldsmith, K. C., MacDonald, T. J., Northcott, P. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10458-9 · Cited by 118
Self-citationCell Lineage-Based Stratification for Glioblastoma
Wang, Z., Sun, D., Chen, Y.-J., Xie, X., Shi, Y., Tabar, V. S., Brennan, C., Bale, T., Jayewickreme, C. D., Laks, D. R., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.003 · Cited by 111
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma
Martin‐García, D., Navarro, A., Valdés‐Mas, R., Clot, G., Gutiérrez‐Abril, J., Prieto, M., Ribera‐Cortada, I., Woroniecka, R., Rymkiewicz, G., Bens, S., et al. (2018) · Blood · doi:10.1182/blood-2018-07-862151 · Cited by 111
The convergent roles of the nuclear factor I transcription factors in development and cancer
Chen, K., Lim, J. W. C., Richards, L. J., & Bunt, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.015 · Cited by 109
Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
Katoh, M. (2019) · Clinical Science · doi:10.1042/cs20180845 · Cited by 107
Franceschi, E., Höfer, S., Brandes, A. A., Frappaz, D., Kortmann, R., Bromberg, J. E. C., Dangouloff‐Ros, V., Boddaert, N., Hattingen, E., Wiestler, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30669-2 · Cited by 124
Self-citationNishiguchi, G., Keramatnia, F., Min, J., Chang, Y., Jonchère, B., Das, S., Actis, M., Price, J. E., Chepyala, D., Young, B. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01313 · Cited by 108
Obstacles to Brain Tumor Therapy: Key ABC Transporters
Wijaya, J., Fukuda, Y., & Schuetz, J. D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122544 · Cited by 106
“Efforts to better delineate Group 3 and Group 4 signatures include integration of genomic, transcriptomic and epigenomic analyses [133,134].”
BackgroundThatikonda, V., Islam, S. M. A., Autry, R. J., Jones, B. C., Gröbner, S. N., Warsow, G., Hutter, B., Hüebschmann, D., Fröhling, S., Kool, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00509-4 · Cited by 107
Self-citationSingle-cell analysis of structural variations and complex rearrangements with tri-channel processing
Sanders, A. D., Meiers, S., Ghareghani, M., Porubskỳ, D., Jeong, H., Vliet, A. V., Rausch, T., Richter‐Pechańska, P., Kunz, J. B., Jenni, S., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0366-x · Cited by 102
“From this, three data layers are considered: (1) the total number of reads in a binned region are measured to calculate the ‘depth’ layer; (2) the relative proportion of W and C reads are measured to calculate the ‘strand’ layer; and (3) the number of W and C reads assigned to H1 or H2 are used to calculate the ‘phase…”
BackgroundMethodSelf-citationBAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation
Zhu, D., Osuka, S., Zhang, Z., Reichert, Z. R., Yang, L., Kanemura, Y., Jiang, Y., You, S., Zhang, H., Devi, N. S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.006 · Cited by 101
“MB has been recently subdivided in four clinically and molecularly distinct subgroups: the wingless (WNT) group, the sonic hedgehog (SHH) group, group 3 and group 4 (Cavalli et al., 2017; Gilbertson and Ellison, 2008; Jones et al., 2012; Northcott et al., 2017).”
InfluentialHirsch, T. Z., Pilet, J., Morcrette, G., Roehrig, A., Monteiro, B. J. E., Molina, L. M., Bayard, Q., Trépo, E., Meunier, L., Caruso, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1809 · Cited by 100
Pfaff, E., Aichmüller, C., Sill, M., Stichel, D., Snuderl, M., Karajannis, M. A., Schuhmann, M. U., Schittenhelm, J., Hasselblatt, M., Thomas, C., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02101-0 · Cited by 99
Self-citationHoldhof, D., Johann, P. D., Spohn, M., Bockmayr, M. L., Safaei, S., Joshi, P. K., Masliah‐Planchon, J., Ho, B., Andrianteranagna, M. J. D. D., Bourdeaut, F., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02250-7 · Cited by 97
Self-citationStenzinger, A., Alber, M., Allgäuer, M., Jurmeister, P. S., Bockmayr, M. L., Budczies, J., Lennerz, J. K., Eschrich, J., Kazdal, D. N., Schirmacher, P., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.011 · Cited by 102
Self-citationCrosstalk of the Wnt/β-Catenin Signaling Pathway in the Induction of Apoptosis on Cancer Cells
Trejo‐Solís, C., Escamilla-Ramírez, Á., Jiménez‐Farfán, D., Castillo‐Rodríguez, R. A., Flores‐Nájera, A., & Cruz-Salgado, A. (2021) · Pharmaceuticals · doi:10.3390/ph14090871 · Cited by 104
Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy
Cacciotti, C., Fleming, A. J., & Ramaswamy, V. (2020) · The Journal of Pathology · doi:10.1002/path.5457 · Cited by 96
“Similar groups have been identified using DNA methylation, with a poor prognosis group enriched for MYC and rarely MYCN [83,95,96].”
BackgroundInfluentialSelf-citationWilliamson, D., Schwalbe, E. C., Hicks, D., Aldinger, K. A., Lindsey, J. C., Crosier, S., Richardson, S., Goddard, J., Hill, R. M., Castle, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111162 · Cited by 87
“Here, we show that, in regard to their transcriptomes, the primary intertumoral variation in MBGrp3/MBGrp4 patients is continuous, in contrast to the discrete nature of the methylation MBGrp3/MBGrp4 subtypes (I–VIII) (Cavalli et al., 2017; Northcott et al., 2017; Schwalbe et al., 2013; Sharma et al., 2019).”
BackgroundMethodInfluentialClinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
Kumar, R., Smith, K. S., Deng, M. Y., Terhune, C., Robinson, G. W., Orr, B. A., Liu, A. P. Y., Lin, T., Billups, C. A., Chintagumpala, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01359 · Cited by 92
“30 (0) 17 (5) 10 (10) 5 (14) 0 (19) 22 (0) 3 (4) 1 (4) 0 (5) 0 (5) Number at Risk (number censored)”
Self-citationLsd1 as a therapeutic target in Gfi1-activated medulloblastoma
Lee, C., Rudneva, V. A., Erkek, S., Zapatka, M., Chau, L. Q., Tacheva-Grigorova, S. K., Garancher, A., Rusert, J. M., Aksoy, O., Lea, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08269-5 · Cited by 86
Self-citationLi, J., Zhao, S., Lee, M., Yin, Y., Li, J., Zhou, Y., Ballester, L. Y., Esquenazi, Y., Dashwood, R. H., Davies, P. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb5427 · Cited by 92
Zhang, Z., Teng, X., Zhao, F. Q., Ma, C., Zhang, J., Xiao, L.-F., Wang, Y., Chang, M., Tian, Y., Li, C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111530 · Cited by 91
Self-citationMenyhárt, O., & Győrffy, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09854-1 · Cited by 91
“APC mutations are coupled with distinct gene expression signatures, suggesting that CTNNB1 and APC mutations are mutually exclusive and molecularly distinct [8].”
BackgroundInfluentialTan, I., Arifa, R. D. D. N., Rallapalli, H., Kana, V., Lao, Z., Sanghrajka, R. M., Bayin, N. S., Tanne, A. J., Wojcinski, A., Korshunov, A., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01536-0 · Cited by 86
Self-citation
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.